Pelvic Doppler Ultrasound and Staging in Persistent Gestational Trophoblastic Neoplasia

First‑Line Imaging Recommendation

• The European Society for Medical Oncology (ESMO) recommends that, in patients with a molar pregnancy who have confirmed persistent or rising β‑hCG after evacuation, a pelvic Doppler ultrasound should be performed immediately as the first investigative step to assess disease burden and guide further management【1】. (Guideline recommendation)

Diagnostic Contributions of Pelvic Doppler Ultrasound

• Pelvic Doppler ultrasound quantifies uterine size and volume, providing an objective measure of intra‑uterine disease burden in gestational trophoblastic neoplasia (GTN)【1】. (Expert consensus)
• The examination evaluates intra‑pelvic spread of GTN, supplying essential information for anatomic staging【1】. (Expert consensus)
• Doppler assessment of the uterine arterial pulsatility index serves as an independent prognostic marker for resistance to single‑agent methotrexate therapy, aiding treatment planning【1】. (Expert consensus)

Staging Sequence After Ultrasound

• A chest X‑ray is mandated as the second imaging study because the lungs are the most frequent site of GTN metastasis【1】. (Guideline recommendation)
• If the chest X‑ray is normal, further imaging is unnecessary; although chest CT can reveal micrometastases in ~40 % of low‑risk patients, these findings do not modify outcome or management in this group【1】. (Evidence from cohort data)
• When the chest X‑ray shows lesions larger than 1 cm, immediate brain MRI and chest/abdomen CT are required to exclude brain or liver metastases, which would substantially alter therapeutic strategy and risk stratification【1】. (Guideline recommendation)
• Initial CT of the chest should not be performed before a chest X‑ray, because detection of micrometastatic disease on CT alone does not influence management decisions in low‑risk GTN【1】. (Guideline recommendation)

Definition of Persistent GTN Requiring Work‑up

• Persistent GTN is diagnosed when two consecutive β‑hCG rises of ≥10 % occur over at least a 2‑week interval (e.g., days 1, 7, 14)【1】.
• It is also diagnosed when four plateaued β‑hCG values are observed over at least a 3‑week interval (e.g., days 1, 7, 14, 21)【1】.
• Persistence of any detectable β‑hCG for ≥6 months after evacuation also meets criteria for work‑up【1】. (All criteria from ESMO guideline)

Critical Management Pitfalls

• Re‑biopsy of residual uterine tissue should be avoided because it carries a high risk of life‑threatening hemorrhage【1】. (Safety warning from guideline)

Risk Stratification After Complete Staging

• Apply the FIGO 2000 prognostic scoring system to determine treatment intensity: scores 0–6 indicate single‑agent methotrexate, whereas scores ≥7 mandate multi‑agent EMA/CO chemotherapy【1】. (Guideline recommendation)
• The uterine Doppler pulsatility index obtained during the initial ultrasound contributes to predicting resistance to single‑agent therapy, supporting the choice of more intensive regimens when a high‑risk index is present【1】. (Prognostic factor identified in guideline)

Initial Staging and Investigation for Persistent β‑hCG after Molar Pregnancy

First‑Line Imaging

• The European Society for Medical Oncology (ESMO) recommends that a pelvic Doppler ultrasound be performed immediately as the first investigation when persistent β‑hCG is confirmed after molar pregnancy evacuation【2】.

Ultrasound Diagnostic Contributions

• Doppler pelvic ultrasound confirms the absence of a new intra‑uterine pregnancy, a prerequisite before initiating chemotherapy【2】.
• It measures uterine size and volume, providing an estimate of disease burden【2】.
• The scan evaluates intra‑pelvic spread of gestational trophoblastic neoplasia (GTN), informing staging decisions【2】.
• Assessment of vascularity using the Doppler pulsatility index serves as an independent prognostic factor for resistance to single‑agent methotrexate therapy【2】.

Definition of Persistent β‑hCG

• Persistent β‑hCG is defined by any of the following patterns after evacuation:

Subsequent Imaging

• Chest X‑ray is the recommended second test because the lungs are the most common site of GTN metastasis【2】.
• If the chest X‑ray is normal, no further imaging is required; although CT can detect micrometastases in ≈ 40 % of patients, these findings do not alter outcome or management in low‑risk disease【2】.
• If the chest X‑ray shows lesions >1 cm, the guideline advises proceeding to MRI of the brain and CT of the chest/abdomen to rule out brain or liver metastases, which would significantly change therapeutic strategy【2】.

Critical Management Pitfalls

• Do not start chemotherapy without first confirming the absence of a new pregnancy by ultrasound, as this could jeopardize a viable gestation【2】.
• Avoid performing a re‑biopsy to confirm malignant transformation of residual tissue because it carries a high risk of life‑threatening hemorrhage【3】.
• Do not order a CT chest as the initial imaging study before a chest X‑ray; micrometastatic disease detected only on CT does not influence management in low‑risk GTN【2】.